Majority of patients with hepatitis C express physical, mental, and social difficulties with antiviral treatment

European Journal of Gastroenterology and Hepatology

Volumn 18, Issue 4, 2006, Pages 381-388

  Zickmund, Susan L ^a,b   Bryce, Cindy L ^a   Blasiole, Julie A ^b   Shinkunas, Laura ^c   LaBrecque, Douglas R ^d   Arnold, Robert M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Adherence; Antiviral therapy; Depression; Fatigue; Hepatitis C; Quality of life

Indexed keywords

ANTIVIRUS AGENT; PEGINTERFERON; RECOMBINANT INTERFERON;

ABSTINENCE; ADULT; ALCOHOL ABSTINENCE; ANOREXIA; ANXIETY DISORDER; COMORBIDITY; CONCENTRATION LOSS; CONFERENCE PAPER; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DRUG FEVER; EMOTIONALITY; EMPLOYMENT; EMPLOYMENT STATUS; FAMILY RELATION; FATIGUE; FEMALE; FLU LIKE SYNDROME; FRIEND; FRUSTRATION; FUNCTIONAL STATUS; HAIR LOSS; HEPATITIS C; HUMAN; HUMAN RELATION; INJECTION SITE REACTION; JOB PERFORMANCE; LIBIDO DISORDER; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEMORY DISORDER; MENTAL DISEASE; MENTAL INSTABILITY; MOOD CHANGE; NAUSEA AND VOMITING; PAIN; PATIENT COMPLIANCE; PHYSICAL DISEASE; PRIORITY JOURNAL; PSYCHOSOCIAL DISORDER; SEMI STRUCTURED INTERVIEW; SIDE EFFECT; SOCIAL INTERACTION; TERTIARY HEALTH CARE; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; ADULT; ANALYSIS OF VARIANCE; ANTIVIRAL AGENTS; COMORBIDITY; CROSS-SECTIONAL STUDIES; DEPRESSION; FATIGUE; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERPERSONAL RELATIONS; MALE; MIDDLE AGED; MIDWESTERN UNITED STATES; PATIENT COMPLIANCE; PREVALENCE; QUALITY OF LIFE;

EID: 33645098992     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200604000-00011     Document Type: Conference Paper

References (27)

1. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90:1562-1569.
2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
3. Maddock C, Baita A, Orru MG, Sitzia R, Costa A, Muntoni E, et al. Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms. J Psychopharmacol 2004; 18:41-46.
4. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061-1069.
5. Ong JP, Younossi ZM. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. Cleve Clin J Med 2004; 71 (suppl 3):S17-S21.
6. Crone CC, Gabriel GM, Wise TN. Managing the neuropsychiatric side effects of interferon-based therapy for hepatitis C. Cleve Clin J Med 2004; 71 (suppl 3):S27-S32.
7. Morgan MG, Fischhoff B, Bostrom A, Atman CJ. Risk communication: a mental models approach. Cambridge, UK: Press Syndicate of the University of Cambridge; 2002.
8. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67:361-370.
9. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981; 19:787-805.
10. Downs JS, Murray PJ, Bruine DB, Penrose J, Palmgren C, Fischhoff B. Interactive video behavioral intervention to reduce adolescent females' STD risk: a randomized controlled trial. Soc Sci Med 2004; 59: 1561-1572.
11. Miller WL, Crabtree BF, editors. Primary care research: a multi typology and qualitative road map. In: Doing qualitative research. London: Sage Press; 1992.
12. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33:159-174.
13. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40:373-383.
14. Raison CL, Broadwell SD, Borisov AS, Manatunga AK, Capuron L, Woolwine BJ, et al. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun 2005; 19:23-27.
15. McDonald J, Jayasuriya J, Bindley P, Gonsalvez C, Gluseska S. Fatigue and psychological disorders in chronic hepatitis C. J Gastroenterol Hepatol 2002; 17:171-176.
16. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1493-1499.
17. Fontana RJ, Schwartz SM, Gebremariam A, Lok AS, Moyer CA. Emotional distress during interferon-alpha-2B and ribavirin treatment of chronic hepatitis C. Psychosomatics 2002; 43:378-385.
18. Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 1999; 29:264-270.
19. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343:1673-1680.
20. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343:1666-1672.
21. Zickmund S, Hillis SL, Barnett MJ, Ippolito L, LaBrecque DR. Hepatitis C virus-infected patients report communication problems with physicians. Hepatology 2004; 39:999-1007.
22. Zickmund S, Ho EY, Masuda M, Ippolito L, LaBrecque DR. "They treated me like a leper". Stigmatization and the quality of life of patients with hepatitis C. J Gen Intern Med 2003; 18:835-844.
23. Sylvestre DL, Loftis JM, Hauser P, Genser S, Cesari H, Borek N, et al. Co-occurring hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care. J Urban Health 2004; 81:719-734.
24. McHutchison JG, Dev AT. Future trends in managing hepatitis C. Gastroenterol Clin North Am 2004; 33 (suppl 1):S51-S61.
25. Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37:443-451.
26. Daniel S. Chronic hepatitis C treatment patterns in African American patients: an update. Am J Gastroenterol 2005; 100:716-722.
27. Manns MP. Adherence to combination therapy: influence on sustained virologic response and economic impact. Gastroenterol Clin North Am 2004; 33 (suppl 1):S11-S24.